Effect of Aprepitant in Patient with Gastroparesis and Related Disorders

Kyoungwon Jung; Moo In Park

doi:10.4166/kjg.2018.72.6.325

Journal List > Korean J Gastroenterol > v.72(6) > 1109932

Go to TopGo to Top Go to BottomGo to Bottom

See the article "".

TOOLS

Jung and Park: Effect of Aprepitant in Patient with Gastroparesis and Related Disorders

Research Update

The Korean Journal of Gastroenterology 2018; 72(6): 325-328.

Published online: 27 December 2018

DOI: https://doi.org/10.4166/kjg.2018.72.6.325

Effect of Aprepitant in Patient with Gastroparesis and Related Disorders

Kyoungwon Jung, Moo In Park

Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

Correspondence to: Moo In Park, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, Korea. Tel: +82-51-990-5205, Fax: +82-51-990-5055, mipark@kosinmed.or.kr

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Pasricha PJ, Yates KP, Sarosiek I, et al. Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology. 2018; 154:65–76.e11.

2. Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004; 127:1592–1622.

3. Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut. 2014; 63:1972–1978.

4. Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology. 2015; 149:1762–1774.e4.

5. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001; 111:Suppl 8A. 106S–112S.

6. Stapleton J, Wo JM. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointest Endosc Clin N Am. 2009; 19:57–72. vi

7. Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am. 2015; 44:97–111.

8. Lacy BE, Parkman HP, Camilleri M. Chronic nausea and vomiting: evaluation and treatment. Am J Gastroenterol. 2018; 113:647–659.

9. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013; 108:18–37. quiz 38.

10. Camilleri M. Novel diet, drugs, and gastric interventions for gastroparesis. Clin Gastroenterol Hepatol. 2016; 14:1072–1080.

11. Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol. 2015; 13:1256–1263.e1.

12. Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut. 1998; 43:395–400.

13. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil. 2010; 16:407–413.

14. Tack J, Camilleri M. New developments in the treatment of gastroparesis and functional dyspepsia. Curr Opin Pharmacol. 2018; 43:111–117.

15. Carbone F, Rotondo A, Andrews CN, et al. 1077 a controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology. 2016; 150:S213–S214.

16. Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil. 2015; 27:324–332.

17. Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology. 2017; 153:1240–1250.e2.

18. Sanger GJ, Pasricha PJ. Investigational drug therapies for the treatment of gastroparesis. Expert Opin Investig Drugs. 2017; 26:331–342.

19. Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr. 2003; 27:277–281.

20. Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014; 722:26–37.

21. Yokoe T, Hayashida T, Nagayama A, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Oncologist. 2018; Oct. 17. [Epub ahead of print].

22. Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016; 92:87–98.

23. Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother. 2012; 46:e38.

24. Fountoulakis N, Dunn J, Thomas S, Karalliedde J. Successful management of refractory diabetic gastroparesis with long-term aprepitant treatment. Diabet Med. 2017; 34:1483–1486.

25. Jacobse J, Mensink H, van der Stoep-Yap MYEC, Kollen WJW, Bresters D, Bredius RGM. Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018; 53:1372–1374.

26. Chong K, Dhatariya K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol. 2009; 5:285–288.

TOOLS

ORCID iDs: Moo In Park
https://orcid.org/0000-0003-2071-6957
Similar articles